Hydroxyapatite as Nanoparticle-based Adjuvant: Leishmaniasis Vaccine Candidate

IF 16.4 1区化学 Q1 CHEMISTRY, MULTIDISCIPLINARY

Accounts of Chemical Research Pub Date : 2024-05-21 DOI:10.2174/0115734110308794240515063752

Kübra Kelleci

{"title":"Hydroxyapatite as Nanoparticle-based Adjuvant: Leishmaniasis Vaccine Candidate","authors":"Kübra Kelleci","doi":"10.2174/0115734110308794240515063752","DOIUrl":null,"url":null,"abstract":"\n\nLeishmaniasis caused by Leishmania protozoa can be fatal if left untreated.\nAn effective and safe human vaccine has still not been produced to eradicate the disease. Among\nvaccine development studies, dead vaccines are still known as the most reliable and cheapest method.\nThe selection of an effective and safe adjuvant is important for killed vaccines. We have not\nfound any studies in which hydroxyapatite particles were used as adjuvants in vaccine research\nagainst leishmaniasis.\n\n\n\nIn this study, spherical Hydroxyapatite (HAp) nanoparticles with dimensions of 100nm\nwere synthesized. Then, these particles were combined with autoclaved L. infantum antigens (ALA)\nto prepare vaccine formulations at different concentrations. To determine the immunogenicity of\nHAp, MTT cell viability analysis, nitric oxide (NO), and cytokine production abilities were investigated\nin vitro in J774 macrophage cells.\n\n\n\nAccording to the study results, it was determined that the cell viability level was 97 % at a\nconcentration of 200 μg/ml, and there was a 10-fold increase in NO production and an approximately\n8.5-fold increase in IL-12 cytokine production ability compared to the control group.\n\n\n\nConsidering the study results and the non-toxic properties of HAp, we have shown that\nHAp can be used as an adjuvant in the development of new leishmania vaccines.\n","PeriodicalId":1,"journal":{"name":"Accounts of Chemical Research","volume":null,"pages":null},"PeriodicalIF":16.4000,"publicationDate":"2024-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Accounts of Chemical Research","FirstCategoryId":"92","ListUrlMain":"https://doi.org/10.2174/0115734110308794240515063752","RegionNum":1,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}

引用次数: 0

Abstract

Leishmaniasis caused by Leishmania protozoa can be fatal if left untreated. An effective and safe human vaccine has still not been produced to eradicate the disease. Among vaccine development studies, dead vaccines are still known as the most reliable and cheapest method. The selection of an effective and safe adjuvant is important for killed vaccines. We have not found any studies in which hydroxyapatite particles were used as adjuvants in vaccine research against leishmaniasis. In this study, spherical Hydroxyapatite (HAp) nanoparticles with dimensions of 100nm were synthesized. Then, these particles were combined with autoclaved L. infantum antigens (ALA) to prepare vaccine formulations at different concentrations. To determine the immunogenicity of HAp, MTT cell viability analysis, nitric oxide (NO), and cytokine production abilities were investigated in vitro in J774 macrophage cells. According to the study results, it was determined that the cell viability level was 97 % at a concentration of 200 μg/ml, and there was a 10-fold increase in NO production and an approximately 8.5-fold increase in IL-12 cytokine production ability compared to the control group. Considering the study results and the non-toxic properties of HAp, we have shown that HAp can be used as an adjuvant in the development of new leishmania vaccines.

查看原文本刊更多论文

羟基磷灰石作为纳米颗粒佐剂：利什曼病候选疫苗

由利什曼原虫引起的利什曼病如果不及时治疗会导致死亡。在疫苗开发研究中，死疫苗仍被认为是最可靠、最廉价的方法。在本研究中，合成了尺寸为 100nm 的球形羟基磷灰石（HAp）纳米颗粒。该研究合成了尺寸为 100nm 的球形羟基磷灰石（HAp）纳米颗粒，然后将这些颗粒与高压灭菌的婴儿嗜血杆菌抗原（ALA）结合，制备出不同浓度的疫苗制剂。为了确定HAp的免疫原性，研究人员在体外对J774巨噬细胞进行了MTT细胞活力分析、一氧化氮（NO）和细胞因子产生能力的研究。考虑到研究结果和 HAp 的无毒特性，我们证明 HAp 可用作开发新型利什曼病疫苗的佐剂。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Accounts of Chemical Research 化学-化学综合

CiteScore

31.40

自引率

1.10%

发文量

312

审稿时长

2 months

期刊介绍： Accounts of Chemical Research presents short, concise and critical articles offering easy-to-read overviews of basic research and applications in all areas of chemistry and biochemistry. These short reviews focus on research from the author’s own laboratory and are designed to teach the reader about a research project. In addition, Accounts of Chemical Research publishes commentaries that give an informed opinion on a current research problem. Special Issues online are devoted to a single topic of unusual activity and significance. Accounts of Chemical Research replaces the traditional article abstract with an article "Conspectus." These entries synopsize the research affording the reader a closer look at the content and significance of an article. Through this provision of a more detailed description of the article contents, the Conspectus enhances the article's discoverability by search engines and the exposure for the research.